One of the latest attempts to boost the body’s defenses against cancer is called adoptive cell transfer, in which patients receive a therapeutic injection of their own immune cells.
This therapy, currently tested in early clinical trials for melanoma and neuroblastoma, has its limitations: Removing immune cells from a patient and growing them outside the body for future re-injection is extremely expensive and not always technically feasible.
Weizmann Institute scientists have now tested in mice a new form of adoptive cell transfer, which overcomes these limitations while enhancing the tumor-fighting ability of the transferred cells. The research, reported recently in Blood, was performed in the lab of Prof. Zelig Eshhar of the Institute’s Immunology Department, by graduate student Assaf Marcus and lab technician Tova Waks.
The new approach should be more readily applicable than existing adoptive cell transfer treatments because it relies on a donor pool of immune T cells that can be prepared in advance, rather than on the patient’s own cells. Moreover, using a method pioneered by Prof. Eshhar more than two decades ago, these T cells are outfitted with receptors that specifically seek out and identify the tumor, thereby promoting its destruction.
In the study, the scientists first suppressed the immune system of mice with a relatively mild dose of radiation. They then administered a controlled dose of the modified donor T cells. The mild suppression temporarily prevented the donor T cells from being rejected by the recipient, but it didn’t prevent the cells themselves from attacking the recipient’s body, particularly the tumor. This approach was precisely what rendered the therapy so effective: The delay in the rejection of the donor T cells gave these cells sufficient opportunity to destroy the tumor.
The Latest Bing News on:
Adoptive cell transfer
- Gene Expression Score May Guide Treatment in Uveal Melanomaon April 18, 2024 at 7:30 am
A gene expression score may be able to predict outcomes of adoptive cell therapy and prevent unnecessary surgeries in patients with uveal melanoma, researchers say.
- TILT Biotherapeutics Presents Clinical Data on TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer at AACR 2024on April 9, 2024 at 7:59 pm
including immune checkpoint blockade or adoptive cell transfer for re-invigoration of the tumor microenvironment. TILT’s approach uses oncolytic viruses to selectively replicate in and lyse ...
- Novel mechanism supports antitumor response and T-cell survivalon April 8, 2024 at 5:00 pm
These specialized T-cell express receptors that recognize specific antigens and stimulate an immune response to attack cancer cells and other foreign antigens. Adoptive cell therapy, a type of ...
- Utilizing interleukin 2 for immune cell activation and expansionon April 2, 2024 at 10:06 pm
Interleukin-2 (IL-2) is a vital cytokine in adoptive cell therapy that plays an important part in the stimulation and growth of immune cells as well as Tumor-Infiltrating Lymphocytes (TIL ...
- Is Immunotherapy Right for Me?on March 25, 2024 at 5:00 pm
Scientists continue to research immunotherapies for lung cancer, including checkpoint inhibitors, therapeutic vaccines, and adoptive cell therapy. They’re also looking to see if combinations of ...
- Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transferon February 19, 2024 at 7:09 am
However, functional analysis and in vivo transfer of MHC multimer-stained cells is hampered by the persistence of T-cell receptor (TCR)–MHC interactions and subsequently induced signaling events.
- Stanley Riddell, MDon January 22, 2024 at 11:13 am
Dr. Riddell’s early studies demonstrated the potential to augment T cell immunity by the adoptive transfer of antigen-specific T cells and uncovered mechanisms by which virally-infected cells evade ...
- NK cell engineering with MaxCyte®on March 30, 2023 at 9:32 pm
1 Combining DARA with the adoptive transfer of CD38 knockout (CD38 KO) NK cells can potentially increase ADCC and reduce DARA-induced fratricide, boosting NK cell persistence. To further enhance ...
- adoptive cell transferon June 3, 2022 at 8:42 am
Stemming from the American Society of Clinical Oncology gathering in Chicago, it will be difficult not to give into the optimism that is cancer research these days. In conjunction with significant ...
- Adoptive Transfer of Splenocytes to Study Cell-mediated Immune Responses in Hepatitis C Infection Using HCV Transgenic Miceon April 28, 2022 at 4:25 am
Lymphocytes were prepared as a cell suspension by gently pressing organ segments through a fine plastic cell strainer using a plastic pipette; then, 10 ml of PBS was added to pass cells through ...
The Latest Google Headlines on:
Adoptive cell transfer
[google_news title=”” keyword=”adoptive cell transfer” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
Cancer treatment
- Prince William 'leaning on unlikely ally' amid Kate Middleton cancer treatment, expert claimson April 27, 2024 at 7:32 am
Prince William has had an 'unlikely ally' that he has been able to lean on, a royal expert has claimed, as his wife Kate undergoes a course of preventative chemotherapy
- Isabella Strahan Gives Brain Cancer Treatment Update After Unexpected Surgeryon April 26, 2024 at 4:30 am
Michael Strahan’s daughter Isabella Strahan shared a health update amid her ongoing brain cancer battle. She revealed her medulloblastoma diagnosis in January.
The Latest Google Headlines on:
Cancer treatment
[google_news title=”” keyword=”cancer treatment” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]